Spyre Therapeutics, Inc. (SYRE) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
SYRE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SYRE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | 100.0% | -27348.0% | -38238.1% |
| 2022 | 100.0% | -3640.2% | -3598.8% |
| 2021 | 100.0% | -350.3% | -351.1% |
Download Data
Export SYRE earnings history in CSV or JSON format
Free sign-in required to download data
Spyre Therapeutics, Inc. (SYRE) Earnings Overview
As of May 8, 2026, Spyre Therapeutics, Inc. (SYRE) reported trailing twelve-month net income of -$179M, reflecting +37.7% year-over-year growth. The company earned $-0.52 per diluted share over the past four quarters.
Looking at the long-term picture, SYRE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$10M in fiscal 2014.
Spyre Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARRY (-$67M net income, -4.1% margin), PRTA (-$151M net income, -2520.6% margin), TRMB ($456M net income, 11.8% margin), SYRE has comparable earnings metrics. Compare SYRE vs ARRY →
SYRE Earnings vs Peers
Earnings metrics vs comparable public companies
SYRE Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$155M | +25.4% | -$210M | $-1.98 | - | - |
| 2024 | -$208M | +38.6% | -$209M | $-3.18 | - | - |
| 2023 | -$339M | -304.2% | -$242M | $-46.15 | -38238.1% | -27348.0% |
| 2022 | -$84M | -27.4% | -$85M | $-24.86 | -3598.8% | -3640.2% |
| 2021 | -$66M | +18.7% | -$66M | $-25.02 | -351.1% | -350.3% |
| 2020 | -$81M | -3.4% | -$81M | $-37.89 | - | - |
| 2019 | -$78M | -76.5% | -$80M | $-61.23 | - | - |
| 2018 | -$44M | -62.8% | -$45M | $-53.25 | -1140.6% | -1169.3% |
| 2017 | -$27M | -25.5% | -$28M | $-45.01 | -523.3% | -531.7% |
| 2016 | -$22M | -92.1% | -$22M | $-55.40 | -468.8% | -473.3% |
Full SYRE Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYRE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SYRE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSYRE — Frequently Asked Questions
Quick answers to the most common questions about buying SYRE stock.
Is SYRE growing earnings?
SYRE EPS is $-0.52, with earnings growth accelerating to +37.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-179M.
What are SYRE's profit margins?
Spyre Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SYRE's earnings?
SYRE earnings data spans 2014-2025. The accelerating earnings trend is +37.7% YoY. Historical data enables comparison across business cycles.